Thymic carcinoma surgery: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Surgery== | ==Surgery== | ||
Treatment options for thymic carcinoma include the following: | |||
*Surgery | |||
*Radiation | |||
Multimodality approach, such as: | |||
*Surgical resection | |||
*Radiation therapy | |||
*Cisplatin-based chemotherapy | |||
For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention. For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.[2] Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy. Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments. Patients with metastatic disease may respond to combination chemotherapy. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Revision as of 16:12, 4 January 2016
|
Thymic Carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymic carcinoma surgery On the Web |
|
American Roentgen Ray Society Images of Thymic carcinoma surgery |
|
Risk calculators and risk factors for Thymic carcinoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Surgery
Treatment options for thymic carcinoma include the following:
- Surgery
- Radiation
Multimodality approach, such as:
- Surgical resection
- Radiation therapy
- Cisplatin-based chemotherapy
For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention. For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.[2] Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy. Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments. Patients with metastatic disease may respond to combination chemotherapy.